Orexigen and Keryx Grind Though Strict Regulatory Process
The Bedford Report Provides Equity Research on Orexigen Therapeutics and Keryx Biopharmaceuticals

Lannett Receives FDA Approval for Loxapine Capsules, 5 MG, 10 MG, 25 MG and 50 MG
Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application of Loxapine Capsules, 5 mg, 10 mg, 25 mg and 50 mg, which are therapeutically equivalent to the reference listed drug, Loxitane Capsules, 5 mg, 10 mg, 25 mg and 50 mg from Watson Pharmaceuticals.